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Over the long term, epilepsy is clearly associated with cognitive impairment. This has 
been demonstrated functionally, using neuropsychological testing, and reinforced by 
structural studies showing progressive atrophy in patients with chronic epilepsy 1-3. The 
prevailing explanation for this, of course, has been the direct and cumulative effects of 
seizures on the brain. The basic science literature is chock full of studies showing 
impairment of neuronal function after seizures, both acutely and chronically. And for 
those of us who see patients, the progressive memory complaints and clear-cut decline 
in function seen in those with drug-resistant epilepsy — particularly temporal lobe 
epilepsy — appear to sufficiently attest to the fact that the seizures are the culprit. 
 
Of course, numerous other factors that might impact upon cognitive function in epilepsy. 
These include direct medication effects, the underlying cause of the epilepsy (e.g. head 
trauma), and depression, which is rampant in the epilepsy population. Critical as these 
may be in determining cognition, one would not expect these, for the most part, to have 
progressive effects; most underlying causes of epilepsy are not progressive, while 
depression’s effects will vary over time even without treatment, and the impact of 
  
medication will be acute rather than cumulative. 
 
But in the review which appears in this issue of the journal, Hamed presents a novel 
hypothesis, backed by considerable evidence, which points in a different direction: 
namely, that epilepsy is strongly associated with accelerated atherosclerosis, and that 
this chronic vascular disease, in turn, may lead to cognitive impairment over time in the 
epilepsy population. This notion and the prevailing view are hardly mutually exclusive; in 
fact, the effects of seizures and those of atherosclerosis could even be synergistic in 
impairing cognitive function. 
 
But is it really true that epilepsy is associated with atherosclerosis? After all, to take the 
general contracting metaphor, we would not expect the wiring in a house to have an 
impact on the plumbing. Yet epidemiologic studies over several decades, from multiple 
populations, using slightly varying endpoints, clearly demonstrate that patients with 
epilepsy have significantly elevated rates of vascular disease 4-8. That such vascular 
disease affects the brain is shown specifically in the elevated rates of stroke seen in 
several of these studies5,8,9. Reverse causation is an important confounder to keep in 
mind, as a fair fraction of epilepsy is caused by ischemic stroke. However, elevated 
rates of vascular disease are seen even in those with idiopathic epilepsy, and in those 
in whom a history of stroke has been specifically excluded5,9. Thus, this is not simply an 
artifact of stroke-induced epilepsy. Furthermore, an even more convincing set of studies 
has demonstrated that carotid intimal-medial thickness (CIMT) is significantly elevated 
in patients with epilepsy compared to controls 10-12. This is noteworthy because CIMT is 
a powerful surrogate marker of atherogenesis; thus, this is rather strong evidence that 
the ischemic disease seen in this population is not due to hypercoagulable states, or 
hemodynamic derangements, but rather from atherosclerotic processes. And, as both 
the literature and common sense will tell you, the accumulation of such vascular 
disease in the brain should inevitably lead to cognitive decline. 
 
Why might this be happening? Hamed reviews an extensive number of intermediate 
markers for vascular disease, each of which shows evidence of greater presence 
among the epilepsy population. One example is obesity, prominent among epilepsy 
patients, which can lead to the metabolic syndrome, diabetes, and vascular disease. 
Another category consists of the many serologic markers of vascular risk which are 
elevated in epilepsy patients, including serum lipids, liproprotein(a) {Lp(a)}, 
homocysteine, C-reactive protein (CRP), and lipid oxidation products10,12. 
 
Yet this only gets us part way down the causal chain, because if these alterations are 
the cause of chronic atherosclerosis in patients with seizures, the next crucial question 
is: what is it about epilepsy that gives rise to all these serologic derangements? One 
could conceive of factors related to the disease itself that might contribute to these 
phenomena, such as cellular inflammation, or alteration of the hypothalamic-pituitary 
axis. Such disease-mediated suggestions are purely speculative, without supporting 
evidence. 
 
So here the editorialist will be more pointed than the author of the review in pointing the 
  
finger where the evidence strongly leads: toward the drugs. Abundant evidence has 
emerged in the last decade to indicate that the older antiepileptic drugs (AEDs), 
especially those which induce the cytochrome P450 system, are specifically associated 
with elevations in lipids, Lp(a), CRP, and HCY 13, with the evidence coming not just from 
cross-sectional studies, but from repeated-measures investigations which leave no 
doubt as to the causative role of the drugs 14-16. CIMT too appears to be associated with 
the older drugs, and is greater with longer duration of exposure, consistent with a 
continuous accumulation process17. So if, indeed, the cognitive decline of epilepsy is 
atherogenic in nature, then the ultimate cause may well be the off-target effects of many 
of the drugs that physicians prescribe. 
 
In a disease like epilepsy, in which almost everyone is treated, it can be hard to 
distinguish the effects of the disease from those of the drugs. But with the profusion of 
new agents over the last 20 years, we should now have the capacity to separate 
individual drug effects from the natural history of the disease. Doing so will be complex, 
however, and will require investigations of varying aims and designs. First, are the 
inducing AEDs associated with end-point vascular disease? Little study has been done 
of this issue9 and much more is needed. Then longitudinal follow-up studies will be need 
to address questions such as: how does the rate of cognitive decline in seizure-free 
patients with epilepsy compare to that of controls? If it is greater, does it correlate with 
atherosclerosis? And if so, does this in turn correlate with the use of enzyme-inducing 
rather than non-inducing AEDs?  
 
These questions should keep us busy for a while, and will be crucial for prevention if 
some of this is disease- rather than drug-related (or, if it is drug-related, for those who 
are obliged to remain on the offending agents). In the meantime, we should keep in 
mind that there are many aspects of home maintenance, and we ill serve our patients if 
we fix their wiring only to gum up their plumbing. 
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